Pioneering research on mechanistic basis of disease in new journal Systems MedicineMarch 13, 2018
New Rochelle, NY, March 13, 2018--The new peer-reviewed journal, Systems Medicine, has launched with a powerful mission to capture the leading research in the emerging field of medical systems biology. A fascinating Roundtable Discussion with key opinion leaders on the importance of systems medicine and interviews with thought leaders highlight the debut of Systems Medicine, a new open access journal from Mary Ann Liebert, Inc., publishers. The articles are available on the Systems Medicine website.
Co-Editors-in-Chief Harald H.H.W. Schmidt, MD, PhD, PharmD, Maastricht University, The Netherlands and Jan Baumbach, PhD, Technical University of Munich, Germany, discuss why the current approach to treating disease fails to drive successful new drug development in their Editorial entitled, "The End of Medicine as We Know It: Introduction to the New Journal, Systems Medicine." Modern omics technology is providing a new way to look at diseases and, combined with advanced molecular tools, a deeper understanding of systems biology, and big data, is enabling new mechanistic definitions of disease.
In an insightful Roundtable Discussion moderated by Dr. Schmidt, the expert panel examines the differences between systems medicine and current medicine and share their views on how systems medicine can help solve some of the problems plaguing classical medicine. Roundtable participants Jan Baumbach, Joseph Loscalzo, Alvar Agusti, Edwin Silverman, and Vasco Azevedo explore how an emphasis on molecular mechanistic biomarkers will help drive major innovations in new drug discovery and the development of novel preventive therapies based on research into the trajectories of healthy aging.
Newly published in Systems Medicine are interviews with two thought leaders on systems medicine: Charles Auffray, PhD, President, European Institute for Systems Biology & Medicine and Chair of the Executive Board, European Association of Systems Medicine, and Weiniu Gan, PhD, Program Director, Division of Lung Diseases, National Heart, Lung, and Blood Institute, U.S. National Institutes of Health.
Systems Medicine: Journal of Medical Systems Biology and Network Medicine is the premier open access, peer-reviewed journal focused on interdisciplinary approaches to exploiting the power of big data by applying systems biology and network medicine. Led by Co-Editors-in-Chief H.H.H.W. Schmidt, MD, PhD, PharmD, Maastricht University, and Jan Baumbach, PhD, Technical University of Munich, Germany, Systems Medicine yields major breakthroughs towards mechanism-based re-definitions of diseases for high-precision diagnostics and treatments. The Journal is collaborative partners with the European Cooperation in Science and Technology (COST), Italian Association for Systems Medicine and Healthcare (ASSIMSS), and European Association for Systems Medicine (EASYM). Complete tables of content can be viewed on the Systems Medicine website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Assay and Drug Development Technologies, Big Data, and OMICS: A Journal of Integrative Biology. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.
Mary Ann Liebert, Inc./Genetic Engineering News
Related Drug Discovery Articles:
Researchers from Kyoto University, MIT, and ETH Zurich have developed a compact drug discovery method using simple models and small data sets.
A research team from the Virginia Tech Center for Drug Discovery has received a $431,126 two-year grant from the National Institutes of Health to make improved versions of a promising compound called MMV008138, or 8138 for short.
A new computational tool called fABMACS is helping scientists see beyond static images of proteins to more efficiently understand how these molecules function, which could ultimately speed up the drug discovery process.
When treated with an anti-cancer drug, ICRF-193, fission yeast produce an 'arched and snapped' phenotype that may be used to screen for other cancer drugs.
In what is being called the first-ever test of open-source drug-discovery, researchers from around the world have successfully identified compounds to pursue in treating and preventing parasite-borne illnesses such as malaria as well as cancer.
The biopharmaceutical company Celgene has become the fifth company to join the 'Neglected Tropical Diseases Drug Discovery Booster' consortium, a new initiative to accelerate and cut the cost of early stage drug discovery for two of the world's most neglected diseases, leishmaniasis and Chagas disease.
Researchers at the Institute for Systems Biology and Center for Infectious Disease Research in Seattle have deciphered how the human pathogen Mycobacterium tuberculosis is able to tolerate the recently approved FDA drug bedaquiline.
Scientists from Insilico Medicine in collaboration with Datalytic Solutions and Mind Research Network trained deep neural networks to predict the therapeutic use of large number of multiple drugs using gene expression data obtained from high-throughput experiments on human cell lines.
A new drug discovery approach has yielded a potential therapy for breast cancer that may be more effective than existing medicines.
The primary method used to test compounds for anti-cancer activity in cells is flawed, Vanderbilt University researchers report May 2 in Nature Methods.
Related Drug Discovery Reading:
Drugs: From Discovery to Approval
by Rick Ng (Author)
The third edition of this best-selling book continues to offer a user-friendly, step-by-step introduction to all the key processes involved in bringing a drug to the market, including the performance of pre-clinical studies, the conduct of human clinical trials, regulatory controls, and even the manufacturing processes for pharmaceutical products.Concise and easy to read, Drugs: From Discovery to Approval, Third Edition quickly introduces basic concepts, then moves on to discuss target selection and the drug discovery process for both small and large molecular drugs. The... View Details
Basic Principles of Drug Discovery and Development
by Benjamin Blass (Author)
Basic Principles of Drug Discovery and Development presents the multifaceted process of identifying a new drug in the modern era, providing comprehensive explanations of enabling technologies such as high throughput screening, structure based drug design, molecular modeling, pharmaceutical profiling, and translational medicine, all areas that have become critical steps in the successful development of marketable therapeutics.
The text introduces the fundamental principles of drug discovery and development, also discussing important drug targets by class, in vitro screening... View Details
Drug Discovery and Development: Technology in Transition, 2e
by Raymond G Hill (Editor)
The modern pharmacopeia has enormous power to alleviate disease, and owes its existence almost entirely to the work of the pharmaceutical industry. This book provides an introduction to the way the industry goes about the discovery and development of new drugs. The first part gives a brief historical account from its origins in the mediaeval apothecaries’ trade, and discusses the changing understanding of what we mean by disease, and what therapy aims to achieve, as well as summarising case histories of the discovery and development of some important drugs. The second part focuses on the... View Details
Drug Discovery: From Bedside to Wall Street
by Tamas Bartfai (Author), Graham V. Lees (Author)
Everyone expects something from the drug industry. Physicians and patients, investors, regulators and administrators all have an active interest. Everyone wants to know what makes drugs ‘work’ medically and economically. Why are drugs so expensive? Is it the drug companies or investors who demand high profits? What governs the pharmacoeconomics? Why are so few diseases treatable?
Drug Discovery opens the windows and doors of the industry telling the story of drug development by using real stories from inside the process.Co-written by Graham Lees and Tamas Bartfai who... View Details
Drug Discovery: Practices, Processes, and Perspectives
by Jie Jack Li (Editor), E. J. Corey (Editor)
Sets forth the history, state of the science, and future directions of drug discovery
Edited by Jie Jack Li and Nobel laureate E. J. Corey, two leading pioneers in drug discovery and medicinal chemistry, this book synthesizes great moments in history, the current state of the science, and future directions of drug discovery into one expertly written and organized work. Exploring all major therapeutic areas, the book introduces readers to all facets and phases of drug discovery, including target selection, biological testing, drug metabolism, and computer-assisted drug... View Details
Bioinformatics and Computational Biology in Drug Discovery and Development
by William T. Loging (Editor)
Computational biology drives discovery through its use of high-throughput informatics approaches. This book provides a road map of the current drug development process and how computational biology approaches play a critical role across the entire drug discovery pipeline. Through the use of previously unpublished, real-life case studies the impact of a range of computational approaches are discussed at various phases of the pipeline. Additionally, a focus section provides innovative visualisation approaches, from both the drug discovery process as well as from other fields that utilise large... View Details
Drug Discovery: A History
by Walter Sneader (Author)
Written by a leading authority with an excellent reputation and ability for writing a good narrative, Drug Discovery: A History is a far cry from simply a list of chemical structures.
This lively new text considers the origins, development and history of medicines that generate high media interest and have a huge social and economic impact on society.
Set within a wide historical, social and cultural context, it provides expanded coverage of pre-twentieth century drugs, the huge advances made in the twentieth century and the latest developments in drug research.... View Details
Peptide-based Drug Discovery: Challenges and New Therapeutics
by Ved Srivastava (Editor), David Thurston (Editor), David Rotella (Editor), Tomi Sawyer (Editor), Andrew Young (Editor), David Sabatino (Editor), Colette Dooley (Editor), Andrei Yudin (Editor), Gangadar J. Sanjayan (Editor), Jane V Aldrich (Editor), Shane Roller (Editor), Ram Dharanipragada (Editor), Kit Lam (Editor), Kamala Kesavan (Editor), Elisabetta Bianchi (Editor), Victor J. Hruby (Editor), Chengzao Sun (Editor), Om Prakash (Editor), Nozer Mehta (Editor), Paul Watt (Editor), Fernando Albericio (Editor)
With potentially high specificity and low toxicity, biologicals offer promising alternatives to small-molecule drugs. Peptide therapeutics have again become the focus of innovative drug development efforts backed up by a resurgence of venture funds and small biotechnology companies.
What does it take to develop a peptide-based medicine? What are the key challenges and how are they overcome? What are emerging therapeutics for peptide modalities? This book answers these questions with a holistic story from molecules to medicine, combining the themes of design, synthesis and... View Details
Drug Discovery Toxicology: From Target Assessment to Translational Biomarkers
by Yvonne Will (Editor), J. Eric McDuffie (Editor), Andrew J. Olaharski (Editor), Brandon D. Jeffy (Editor)
As a guide for pharmaceutical professionals to the issues and practices of drug discovery toxicology, this book integrates and reviews the strategy and application of tools and methods at each step of the drug discovery process.
• Guides researchers as to what drug safety experiments are both practical and useful
• Covers a variety of key topics – safety lead optimization, in vitro-in vivo translation, organ toxicology, ADME, animal models, biomarkers, and –omics tools
• Describes what experiments are possible and useful and offers a view into the future,... View Details
Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval (Cancer Drug Discovery and Development)
by Beverly A. Teicher (Editor), Paul A. Andrews (Editor)
This unique volume traces the critically important pathway by which a "molecule" becomes an "anticancer agent. " The recognition following World War I that the administration of toxic chemicals such as nitrogen mustards in a controlled manner could shrink malignant tumor masses for relatively substantial periods of time gave great impetus to the search for molecules that would be lethal to specific cancer cells. Weare still actively engaged in that search today. The question is how to discover these "anticancer" molecules. Anticancer Drug Development Guide: Preclinical Screening, Clinical... View Details